Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LEO Pharma Pays $1 Billion To Get Its Psoriasis Drugs Back From Warner Chilcott

This article was originally published in The Pink Sheet Daily

Executive Summary

American dermatology dream: Danish specialty pharma plans to establish beachhead up in New Jersey after buying back U.S. rights.

You may also be interested in...



Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe

Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.

Novo Nordisk Faced Tough Decision in Greece: Cut Prices And Make A Loss Or Oppose Government Plans

Danish drug maker turns up pressure on Greek government to reverse its price cut demands.

Novo Nordisk Faced Tough Decision in Greece: Cut Prices And Make A Loss Or Oppose Government Plans

Danish drug maker turns up pressure on Greek government to reverse its price cut demands.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel